Literature DB >> 29636886

COX-2 contributes to LPS-induced Stat3 activation and IL-6 production in microglial cells.

Jie Zhu1,2, Shuzhen Li1,3,4, Yue Zhang1,3,4, Guixia Ding1,3,4, Chunhua Zhu1,3,4, Songming Huang1,3,4, Aihua Zhang1,3,4, Zhanjun Jia1,3,4, Mei Li1,2.   

Abstract

Many stimuli including lipopolysaccharide (LPS) could activate microglial cells to subsequently cause inflammatory nerve injury. However, the mechanism of LPS-induced neuroinflammation in microglial cells is still elusive. Thus, the present study was undertaken to examine the role of COX-2 in mediating the activation of Stat3 and the production of IL-6 in BV2 cells challenged with LPS. After 24 h treatment, LPS dose-dependently enhanced COX-2 expression at both mRNA and protein levels. Meanwhile, IL-6 with other inflammatory cytokines including IL-1β, TNF-α, and MCP-1 were similarly enhanced by LPS. Then a specific COX-2 inhibitor (NS-398) was administered to BV2 before LPS treatment. Significantly, COX-2 inhibition suppressed the upregulation of IL-6 at both mRNA and protein levels in line with the trend blockade on IL-1β, TNF-α, and MCP-1. Stat3 drives proinflammatory signaling pathways and contributes to IL-6 production via a transcriptional mechanism in many diseases. Here we found that inhibition of COX-2 entirely blocked LPS-induced Stat3 phosphorylation, which might contribute to the blockade of IL-6 production to some extent. Meanwhile, COX-2 siRNA approach largely reproduced the phenotypes shown by specific COX-2 inhibitor in LPS-treated BV2 cells. Together, these findings suggested that COX-2 might contribute to LPS-induced IL-6 production possibly through activating Stat3 signaling pathway in microglial cells.

Entities:  

Keywords:  COX-2; IL-6; LPS; Microglial cells; Stat3

Year:  2018        PMID: 29636886      PMCID: PMC5883137     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  31 in total

1.  Proinflammatory cytokine expression contributes to brain injury provoked by chronic monocyte activation.

Authors:  A L Sirén; R McCarron; L Wang; P Garcia-Pinto; C Ruetzler; D Martin; J M Hallenbeck
Journal:  Mol Med       Date:  2001-04       Impact factor: 6.354

2.  mPGES-1-derived prostaglandin E2 stimulates Stat3 to promote podocyte apoptosis.

Authors:  Jing Yu; Yimei Wu; Lu Wang; Wen Zhang; Man Xu; Jiayu Song; Yu Fu; Yiyun Cui; Wei Gong; Shuzhen Li; Weiwei Xia; Songming Huang; Aihua Zhang; Zhanjun Jia
Journal:  Apoptosis       Date:  2017-11       Impact factor: 4.677

3.  Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3.

Authors:  Ming-Jiang Xu; Dechun Feng; Hailong Wu; Hua Wang; Yvonne Chan; Jay Kolls; Niels Borregaard; Bo Porse; Thorsten Berger; Tak W Mak; Jack B Cowland; Xiaoni Kong; Bin Gao
Journal:  Hepatology       Date:  2015-02       Impact factor: 17.425

4.  Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis.

Authors:  Zhanjun Jia; Ningning Wang; Toshinori Aoyagi; Haiping Wang; Haiying Liu; Tianxin Yang
Journal:  Kidney Int       Date:  2010-09-15       Impact factor: 10.612

5.  Withaferin A down-regulates lipopolysaccharide-induced cyclooxygenase-2 expression and PGE2 production through the inhibition of STAT1/3 activation in microglial cells.

Authors:  Kyoung-Jin Min; Kyounghwa Choi; Taeg Kyu Kwon
Journal:  Int Immunopharmacol       Date:  2011-03-21       Impact factor: 4.932

6.  Protective effects of urinary trypsin inhibitor on vascular permeability following subarachnoid hemorrhage in a rat model.

Authors:  Ning Zhou; Ting Xu; Ying Bai; Sherchan Prativa; Jia-Zhou Xu; Kai Li; Hong-Bin Han; Jun-Hao Yan
Journal:  CNS Neurosci Ther       Date:  2013-05-22       Impact factor: 5.243

Review 7.  Interleukin-6 and cardiovascular diseases.

Authors:  Tsugiyasu Kanda; Takashi Takahashi
Journal:  Jpn Heart J       Date:  2004-03

8.  Constitutive excessive erythrocytosis causes inflammation and increased vascular permeability in aged mouse brain.

Authors:  O O Ogunshola; M Moransard; M Gassmann
Journal:  Brain Res       Date:  2013-07-26       Impact factor: 3.252

Review 9.  Breaking the barrier in stroke: what should we know? A mini-review.

Authors:  Cesar V Borlongan; Antonio A Rodrigues; Maria Carolina Oliveira
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

10.  Berberine Inhibits Invasion and Metastasis of Colorectal Cancer Cells via COX-2/PGE2 Mediated JAK2/STAT3 Signaling Pathway.

Authors:  Xuan Liu; Qing Ji; Naijing Ye; Hua Sui; Lihong Zhou; Huirong Zhu; Zhongze Fan; Jianfeng Cai; Qi Li
Journal:  PLoS One       Date:  2015-05-08       Impact factor: 3.240

View more
  4 in total

Review 1.  Microglia: Agents of the CNS Pro-Inflammatory Response.

Authors:  José A Rodríguez-Gómez; Edel Kavanagh; Pinelopi Engskog-Vlachos; Mikael K R Engskog; Antonio J Herrera; Ana M Espinosa-Oliva; Bertrand Joseph; Nabil Hajji; José L Venero; Miguel A Burguillos
Journal:  Cells       Date:  2020-07-17       Impact factor: 6.600

2.  AXL Inhibits Proinflammatory Factors to Relieve Rheumatoid Arthritis Pain by Regulating the TLR4/NF-κB Signaling Pathway.

Authors:  Guangzan Zhou; Hang Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-09       Impact factor: 2.650

3.  A potent and selective inhibitor for the modulation of MAGL activity in the neurovasculature.

Authors:  Alicia M Kemble; Benoit Hornsperger; Iris Ruf; Hans Richter; Jörg Benz; Bernd Kuhn; Dominik Heer; Matthias Wittwer; Britta Engelhardt; Uwe Grether; Ludovic Collin
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

4.  Neuroprotective Effect of Clobenpropit against Lipopolysaccharide-Induced Cognitive Deficits via Attenuating Neuroinflammation and Enhancing Mitochondrial Functions in Mice.

Authors:  Vasudevan Mani; Minhajul Arfeen; Hussein M Ali; Abdel-Moneim Hafez Abdel-Moneim; Maha Aldubayan; Ahmad Alhowail
Journal:  Brain Sci       Date:  2021-12-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.